SpectraCure Valuation
| SPEC Stock | SEK 1.22 0.23 15.86% |
Today, the company appears to be fairly valued. SpectraCure AB has a current Real Value of kr1.4 per share. The regular price of the company is kr1.22. Our model measures the value of SpectraCure AB from inspecting the company fundamentals such as Current Valuation of 561.51 M, return on equity of -0.15, and Shares Owned By Insiders of 21.26 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that SpectraCure's price fluctuation is dangerous at this time. Calculation of the real value of SpectraCure AB is based on 3 months time horizon. Increasing SpectraCure's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
SpectraCure's intrinsic value may or may not be the same as its current market price of 1.22, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.22 | Real 1.4 | Hype 1.45 | Naive 1.43 |
The intrinsic value of SpectraCure's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SpectraCure's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SpectraCure AB helps investors to forecast how SpectraCure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SpectraCure more accurately as focusing exclusively on SpectraCure's fundamentals will not take into account other important factors: SpectraCure Total Value Analysis
SpectraCure AB is at this time anticipated to have takeover price of 561.51 M with market capitalization of 565.68 M, debt of 2.49 M, and cash on hands of 129.69 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the SpectraCure fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
561.51 M | 565.68 M | 2.49 M | 129.69 M |
SpectraCure Investor Information
About 21.0% of the company outstanding shares are owned by corporate insiders. The book value of SpectraCure was at this time reported as 1.61. The company recorded a loss per share of 0.26. SpectraCure AB had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from SpectraCure's historical financial statements, SpectraCure AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.SpectraCure Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SpectraCure has an asset utilization ratio of 3.02 percent. This implies that the Company is making kr0.0302 for each dollar of assets. An increasing asset utilization means that SpectraCure AB is more efficient with each dollar of assets it utilizes for everyday operations.SpectraCure Ownership Allocation
SpectraCure AB shows a total of 97.13 Million outstanding shares. SpectraCure AB maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.SpectraCure Profitability Analysis
The company reported the revenue of 5.75 M. Net Loss for the year was (23.34 M) with profit before overhead, payroll, taxes, and interest of 2.99 M.About SpectraCure Valuation
The stock valuation mechanism determines SpectraCure's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of SpectraCure AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of SpectraCure. We calculate exposure to SpectraCure's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SpectraCure's related companies.8 Steps to conduct SpectraCure's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates SpectraCure's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct SpectraCure's valuation analysis, follow these 8 steps:- Gather financial information: Obtain SpectraCure's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine SpectraCure's revenue streams: Identify SpectraCure's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research SpectraCure's industry and market trends, including the size of the market, growth rate, and competition.
- Establish SpectraCure's growth potential: Evaluate SpectraCure's management, business model, and growth potential.
- Determine SpectraCure's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate SpectraCure's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.